Start Sedating a dog when traveling

Sedating a dog when traveling

The organisers had originally considered me for Campath (or Lemtrada) for two reasons: While I could not be included in the CAMMS223 trial, the organisers felt that they had promised me a treatment and therefore could not now ignore me.

Suffice it to say, my initial impressions of the ward I was destined to stay on were fairly grim.

Those views didn't change much over the course of the week.

I experienced few side effects from the steroids, which surprised me as I'd never had them before.

I did suffer the unpleasant metallic taste, a feeling of restlessness (tired but with a mind that couldn't rest) and a light-headedness, which affected my balance.

The infusion lasted for 4 hours, and consisted of 20mg of Campath (or Lemtrada). The time taken to give the infusion was reduced each day as my body grew accustomed to the treatment.

My most significant symptoms of the day were a persistent mild headache and a general overwhelming feeling of weakness.

I was considered for Campath (or Lemtrada) in August 2002.

I was accepted for the CAMMS223 trial of Campath (or Lemtrada) versus beta interferon, but changes to the trial protocol, and the unclear date of my first symptoms, meant I had to be excluded.

I had blood taken to check for base levels of lymphocytes and other blood chemistry.

I had a cannula inserted in my arm, which was to stay there for the rest of the week.

Instead, they offered me Campath (or Lemtrada) on a compassionate basis, for which I cannot thank them enough. I was being offered the potentially more powerful drug, did not risk being randomly chosen to take Rebif (the beta-interferon drug chosen to compare with Campath), and did not have to endure the ghastly pre-treatment MRIs.